MeCP2 expression in human cerebral cortex and lymphoid cells: Immunochemical characterization on a novel higher-molecular-weight form

Journal of Child Neurology

Volumn 18, Issue 10, 2003, Pages 675-682

  Jarrar, Mohammed H ^a   Danko, Charles G ^a   Reddy, Sriram ^a   Lee, Ye Jin M ^a   Bibat, Genila ^a   Kaufmann, Walter E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL CPG BINDING PROTEIN 2; PROTEIN ANTIBODY;

ADOLESCENT; ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BRAIN CORTEX; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; CHILD; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; LYMPHOBLAST; LYMPHOID CELL; MOLECULAR WEIGHT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RETT SYNDROME; SYNAPSE; SYNAPTIC TRANSMISSION; TRANSCRIPTION REGULATION;

EID: 0242624588     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738030180101001     Document Type: Article

References (29)

1. Naidu S: Rett syndrome: A disorder affecting early brain growth. Ann Neurol 1997;42:3-10.
2. van den Veyver IB, Zoghbi HY: Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome. Brain Dev 2001;23(Suppl 1):S147-S151.
3. Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997;88: 471-481.
4. Ballestar E, Wolfe AP: Methyl-CpG binding proteins: Targeting specific gene repression. Eur J Biochem 2001;268:1-6.
5. Akbarian S, Chen RZ, Gribnau J, et al: Expression pattern of the Rett syndrome gene MeCP2 in primate prefrontal cortex. Neurobiol Dis 2001;8:784-791.
6. Johnston MV, Jeon OH, Pevsner J, et al: Neurobiology of Rett syndrome: A genetic disorder of synapse development. Brain Dev 2001;23(Suppl 1):S206-S213.
7. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY: Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 2002;11:115-124.
8. LaSalle JM, Goldstine J, Balmer D, Greco CM: Quantitative localization of heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression phenotypes in normal and Rett syndrome brain by laser scanning cytometry. Hum Mol Genet 2001;10:1729-1740.
9. Aber KM, Nori P, MacDonald S, et al: Methyl-CpG-binding protein 2 is localized in the postsynaptic compartment: An immunochemical study of subcellular fractions. Neuroscience 2003;116: 77-80.
10. Paratcha G, Stein ML, Szapiro G, et al: Experience-dependent decrease in synaptically localized Fra-1. Mol Brain Res 2000;70: 120-130.
11. Eberwine J, Miyashiro K, Kacharmina JK, Job C: Local translation of classes of mRNAs that are targeted to neuronal dendrites. Proc Natl Acad Sci USA 2001;98:7080-7085.
12. Kaufmann WE, Jarrar MH, MacDonald SM: MeCP2 expression in human neocortex. Brain Dev 2002;24:392.
13. Brown V, Jin P, Ceman S, et al: Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001;107:477-487.
14. Mole L, Margolis D, Carroll R, et al: Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in Vacutainer CPT and standard Vacutainer tubes. J Clin Microbiol 1994;32:2212-2215.
15. Lewis JD, Meehan RR, Henzel WJ, et al: Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992;105:487-497.
16. Huttner WB, Scheibler W, Greengard P, De Camilli P: Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III: Its association with synaptic vesicle preparation. J Cell Biol 1983;96: 1374-1388.
17. Sun H-T, Cohen S, Kaufmann WE: Annexin 1 is abnormally expressed in FRAGILE X syndrome: A two-dimensional electrophoresis study in lymphocytes. Am J Med Genet 2001; 103:81-90.
18. Kaufmann WE, Abrams MT, Chen W, Reiss AL: Genotype, molecular phenotype, and cognitive phenotype: Correlations in fragile X syndrome. Am J Med Genet 1999;83:286-295.
19. Wan M, Zhao K, Lee SS, Francke U: MECP2 truncating mutations cause histone H4 hyperacetylation in Rett syndrome. Hum Mol Genet 2001;10:1085-1092.
20. Kudo S, Nomura Y, Segawa M, et al: Functional analyses of MeCP2 mutations associated with Rett syndrome using transient expression systems. Brain Dev 2001;23(Suppl 1):S165-S173.
21. Kaufmann WE, MacDonald SM, Altamura C: Dendritic cytoskeletal protein expression in mental retardation: An immunohistochemical study of the neocortex in Rett syndrome. Cereb Cortex 2000;10:992-1004.
22. Hoffbuhr KC, Moses LM, Jerdonek MA, et al: Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. Ment Retard Dev Disabil Res Rev 2002;8:99-105.
23. Oda Y: Choline acetyltransferase: The structure, distribution and pathologic changes in the central nervous system. Pathol Int 1999;49:921-937.
24. Traynor J, Agarwal P, Lazzeroni L, Francke U: Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Med Genet 2002;3:12.
25. Balmer D, Arredondo J, Samaco RC, LaSalle JM: MECP2 mutations in Rett syndrome adversely affect lymphocyte growth, but do not affect imprinted gene expression in blood or brain. Hum Genet 2002;110:545-552.
26. Geiman TM, Robertson KD: Chromatin remodeling, histone modifications, and DNA methylation - How does it all fit together? J Cell Biochem 2002;87:117-125.
27. Shahbazian MD, Zoghbi HY: Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations. Curr Opin Neurol 2001;14:171-176.
28. Weaving LS, Williamson SL, Bennetts B, et al: Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. Am J Med Genet 2003;118A:103-114.
29. Kaufmann WE: Cortical development in Rett syndrome: Molecular, neurochemical, and anatomical aspects, in Kerr A, Engerström IW (eds): The Rett Disorder and the Developing Brain. Oxford, UK, Oxford University Press, 2001, 85-110.